Diagnosis and Treatment/Original Articles
LI Xu, CHEN Congxia, LIU Fugeng, CUI Yan, ZHU Hui, YAO Zhiming
Objective To investigate the clinical value of diffusely increased bone marrow 18F-fluorodeoxyglucose(18F-FDG) uptake in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL). Methods A retrospective analysis was performed on the clinical data of 114 inpatients who underwent positron emission tomography (PET)/computed tomography examination and were newly diagnosed with DLBCL. All patients underwent bone marrow biopsy. The Chi-square test was used to analyze categorical data, and the t-test or Wilcoxon test was used to analyze continuous data. Results According to the type of bone marrow 18F-FDG uptake, the patients were divided into normal bone marrow group (nPET, 51.8%), only focal group (fPET, 10.5%), only diffuse group (odPET, 28.1%), and focal + diffuse group (f + dPET, 9.6%), with proportions of bone marrow involvement of 0%, 100%, 15.6%, and 100%, respectively, and proportions of stage IV lymphoma of 33.9%, 100%, 59.4%, and 100%, respectively. Compared with the nPET patients, the odPET patients were significantly younger (57 ±17 y vs 70 ±13 y), and had a significantly lower hemoglobin level(108.1 ±23.8 g/dL vs 119.4 ±19.0 g/dL) and significantly higher proportions of stage IV lymphoma and B symptoms (59.4%, 46.9% vs 33.9%, 22.0%, all P < 0.05). There were no significant differences in sex ratio, white blood cell count, frequency of lactate dehydrogenase (LDH) increase, and the proportion of International Prognostic Index (IPI) score > 2. Conclusion Among patients with newly diagnosed DLBCL, patients with diffusely increased bone marrow 18F-FDG uptake are younger than those with normal bone marrow 18F-FDG uptake. They are more prone to bone marrow involvement, stage IV lymphoma, anemia, B symptoms, elevated LDH, and IPI score > 2, which suggest a more serious condition and possibly worse prognosis.